Dyne Therapeutics (DYN) to Release Earnings on Monday

Dyne Therapeutics (NASDAQ:DYN) is projected to release its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.99) per share for the quarter.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Dyne Therapeutics Trading Down 0.3%

NASDAQ DYN opened at $11.16 on Friday. Dyne Therapeutics has a one year low of $6.36 and a one year high of $47.45. The company’s 50 day moving average price is $10.62 and its 200 day moving average price is $11.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -2.89 and a beta of 1.08.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, July 14th. The stock was purchased at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer directly owned 242,179 shares of the company’s stock, valued at approximately $2,206,250.69. This represents a 70.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 14.14% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning lifted its holdings in Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares during the last quarter. Caxton Associates LLP acquired a new stake in Dyne Therapeutics in the 1st quarter valued at about $157,000. AQR Capital Management LLC acquired a new stake in Dyne Therapeutics in the 1st quarter valued at about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after acquiring an additional 366,183 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on DYN shares. Evercore ISI restated an “outperform” rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Jones Trading initiated coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They set a “buy” rating and a $30.00 price objective on the stock. Sanford C. Bernstein initiated coverage on shares of Dyne Therapeutics in a research note on Tuesday, June 24th. They set a “market perform” rating and a $13.00 price objective on the stock. Robert W. Baird dropped their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 18th. Finally, HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.94.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.